Exact Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated wit…
Medical - Diagnostics & Research
US, Madison [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 69.56 | -311.51 | -1023.35 | |
| Graham Fair Price | 47.52 | 15.29 | 10.36 | |
| PEG | 2107.48 | -0.24 | 0.01 | |
| Price/Book | -3.79 | 4.10 | 4.26 | |
| Price/Cash Flow | -72.34 | -107.03 | 386.95 | |
| Prices/Earnings | 56.74 | -29.12 | -67.31 | |
| Price/Sales | -2.77 | 20.14 | 20.71 | |
| Price/FCF | -72.34 | -107.03 | 386.95 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -0.16 | 0.73 | 0.73 | |
| Operating Margin | -59.58 | -0.17 | -0.10 | |
| ROA | -124.79 | -0.02 | < 0.005 | |
| ROE | -0.02 | -0.04 | -122.39 | |
| ROIC | -0.01 | -0.02 | -62.19 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | 0.03 | -99.31 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -10.91 | -0.57 | 94.75 | |
| EPS QOQ | -62.36 | -1.22 | 98.04 | |
| FCF QOQ | 42.92 | -4.46 | -89.60 | |
| Revenue QOQ | 0.03 | -0.01 | -50.98 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 66.77 | 68.01 | 1.85 | |
| Days Sales Outstanding (DSO) | 28.33 | 33.96 | 19.89 | |
| Inventory Turnover | 1.35 | 1.32 | -1.81 | |
| Debt/Capitalization | 0.45 | 0.45 | 0.23 | |
| Quick Ratio | 1.91 | 1.30 | -31.66 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Balanced
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 17.37 | 17.18 | -1.08 | |
| Cash | 4.29 | 3.58 | -16.71 | |
| Capex | -0.19 | -0.21 | -7.08 | |
| Free Cash Flow | 0.19 | -0.66 | 244.09 | |
| Revenue | 3.57 | 3.50 | -2.12 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Weak